Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Celldex Provides Corporate Update and Reports Third Quarter 2019 Results
01:01pm, Tuesday, 12'th Nov 2019
HAMPTON, N.J., Nov. 12, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019..
Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs
01:01pm, Monday, 11'th Nov 2019
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s preclinical pipeline this weekend. A review of the CDX-0159 early development program was presented at the American College of A
CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study
12:30pm, Friday, 08'th Nov 2019
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s ongoing CD40 agonist program today at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting. CD40, expressed on d
